🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A few days left to apply for the ESMO LGP Asia. A once-in-a-lifetime opportunity for young qualified medical or clinical oncologists in the Asia-Pacific region to grow professionally & learn more about ESMO. Apply by 24 April 2023 bit.ly/3ZDiMQa

Congrats to Lorenzo Dottorini etal Journal of Clinical Oncology #adjuvant #CRCsm #olderadults ⌛️#throwback ➡️ consistent with McLeary etal #ACCENT pooled analysis from 10y ago👇 ✅ now confirmed with this more contemporary systematic review 📌 no established benefit of adjuvant oxali in age >70y

Clinical trials are changing health outcomes but travel is still a barrier for regional, remote patients - ABC News abc.net.au/news/2023-05-2…

Very proud to be part of this wonderful team who authored this paper led by Kristina Jenei & Bishal Gyawali, MD, PhD, FASCO #hta #cancermedicines sciencedirect.com/science/articl…

Thanks UroToday.com for highlighting our Trial in Progress, #GUIDE, an ANZUP study in #prostatecancer evaluating the clinical utility of mGSTP1 as a de-escalation strategy . Trial led by PI Kate Mahon and recruiting at eight Australian centres.

BREAKING NEWS Schrag et al publish PROSPECT trial in @nejm. No diff in LRFS, DFS betw neoadj chemo vs CRT in locally advanced Rectal CA. Non-inferiority achieved. #ASCRS23 Roel Hompes Steven D Wexner MD, PhD ASCRS_1 Hagen Kennecke Jonathan Loree Ahmer Karimuddin Marylise Boutros Antonio Caycedo-Marulanda MD, MSc.

NeoCol trial: Neoadj chemo (3 cycles of CAPOX) for T3-4 colon cancer was no better than standard adjuvant chemo. #ASCO23

A privilege on behalf of the study group to present the results from the interim feasibility analyses of the OPTIMISE study at #WCGIC2023. Looking forward to further discussion at the poster session Saturday🧬 🩸ctDNA-guided treatment in oligometastatic CRC

Save the date for the ESMO Gastrointestinal Cancers Congress 2024, on 26-29 June, in Munich, Germany. Be ready to share your latest studies on effectively implementing recent discoveries to improve the lives of patients w/ #GIcancers. ow.ly/mzLz50PPwT0 #ESMOGI24

Marliese Alexander kate Craig Underhill Javier Torres Jeanne Tie David Ball AO Michael MacManus Peter Mac Research University of Melbourne Peter Mac Pharmacy Research Congrats Marliese Alexander - fantastic investigator initiated trial will great collaborations and innovative use of Telehealth 👏🏽👏🏽

The ESMO Gastrointestinal Cancers Congress 2024 programme now online. A great occasion to learn about latest insights into molecular prevention, diagnosis & precision therapy of #GastrointestinalCancers, & more. ow.ly/HVUF50PWyOs #ESMOGI24 @DucreuxMichel Teresa Macarulla

#ESMO23: Positive results from the use of #ctDNA for #MRD assessment in #ColorectalCancer, but sensitivity and specificity of different assays still limit interpretation and validation for #ClinicalPractice @UmbertoMlapel1 Jeanne Tie #ESMODailyReporter 👉dailyreporter.esmo.org/esmo-congress-…

So well deserved 👏👏. A flawless presentation on the role of immune tolerance in colorectal cancer.

Why You Should Attend #WCGIC2024 The World Congress on Gastrointestinal Cancer has a rich history of providing medical oncologists with the expertise needed to help their patients continue to live their lives the best way possible. The 26th year is no exception. Invite your

📢Less than three weeks away Come and join us at #ESMOGI24 🎊 ☑️New trials in GI cancers ☑️Educational sessions ☑️Great #ESMOYOC activities ➕Bonus: Beautiful Munich 🇩🇪🇩🇪 ESMO - Eur. Oncology Chiara Cremolini Jeanne Tie Hanneke van Laarhoven Dr. Cathy Eng @DucreuxMichel Teresa Macarulla ESOncology

🙏 for support and attending on last day. Look forward to trials of Claudin18.2 ADCs demonstrating efficacy against standard of care and establishing Claudin 18.2 as predictive biomarker in addition to HER2 for ADCs! Can we ⬆️ upper GI cancer outcomes with 🎯 💊💉ESMO - Eur. Oncology

It was so great to meet and chat to the architects from McBride Charles Ryan Peter Mac Cancer Centre Open House with my parents on the weekend and hear how they designed the inspiring spiral structure to meet the needs of a hospital but still be inspiring and calming for staff and patients.

I am really excited that we finally got this trial done and published after many many years of hard work and recruiting patients during the pandemic. Next step is to try and get funded access to comprehensive genomic sequencing for our CUP patients, which won't be easy

The DESTINY-CRC02 trial Multicenter, phase 2 study evaluating the efficacy and safety of two doses of trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) in patients with pretreated HER2-positive metastatic #ColorectalCancer , including those with RAS🧬mutations. The trial

Really proud to see SPACE-FLOT published ⁦BJS⁩, helping to tailor adj FLOT for OG Ca. Huge effort, thanks+++ to our global co-authors in 43 centers. ⁦Lorenzo Ferri MD PhD⁩ ⁦David Watson⁩ ⁦Sheraz Markar⁩ ⁦⁦⁦Claire Donohoe⁩ academic.oup.com/bjs/article-ab…